Are incorrectly used drugs more frequently involved in adverse drug reactions? A prospective study

European Journal of Clinical Pharmacology

Volumn 61, Issue 3, 2005, Pages 231-236

  Jonville Bera A P ^a   Bera F ^a   Autret Leca, E ^a  

^a UNIVERSITY HOSPITAL OF TOURS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACENOCOUMAROL; ANTILIPEMIC AGENT; ANTIULCER AGENT; ANXIOLYTIC AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARBAMAZEPINE; DEXTROPROPOXYPHENE; DICLOFENAC; DIPYRONE; DOXYCYCLINE; ETHINYLESTRADIOL PLUS NORGESTREL; HISTAMINE H1 RECEPTOR ANTAGONIST; HISTAMINE H2 RECEPTOR ANTAGONIST; HYPNOTIC AGENT; METFORMIN; PHLOROGLUCINOL; RETINOID; SEROTONIN UPTAKE INHIBITOR;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG LABELING; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG USE; FEMALE; HUMAN; MALE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROBABILITY; SIDE EFFECT; TREATMENT CONTRAINDICATION;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ANALGESICS, NON-NARCOTIC; ANALGESICS, OPIOID; ANTILIPEMIC AGENTS; CALCIUM CHANNEL BLOCKERS; CARBAMAZEPINE; DRUG INFORMATION SERVICES; DRUG INTERACTIONS; HUMANS; MEDICATION ERRORS; PROPOXYPHENE; PROSPECTIVE STUDIES; SEROTONIN UPTAKE INHIBITORS; TIME FACTORS;

EID: 20044372768     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-004-0881-6     Document Type: Article

References (26)

1. Bégaud B, Evreux JC, Jouglard J, Lagier G (1985) Imputabilité des effets inattendus ou toxiques des médicaments. Actualisation de la méthode utilisée en France. Therapie 40:111-118
2. Pouyanne P, Haramburu F, Imbs JL, Bégaud B (2000) Admissions to hospital caused by adverse drug reactions: cross sectional incidence study. BMJ 320:1036
3. Imbs JL, Pouyanne P, Haramburu F, Welsch M, Decker N, Blayac JP et al (1999) et le réseau des Centres régionaux de Pharmacovigilance (CRPV) latrogénie médicamenteuse: estimation de sa prévalence dans les hôpitaux publics français. Thérapie 54:21-27
4. Lacost-Roussillon C, Pouyanne P, Haramburu F, Miremont G, Begaud B (2001) Incidence of serious adverse drug reactions in general practice: a prospective study. Clin Pharmacol Ther 69:458-462
5. Pearson TF, Pittman DG, Longley JM, Grapes ZT, Vigliotti DJ, Mullis SR (1994) Factors associated with preventable adverse drug reactions. Am J Hosp Pharm 51:2268-2272
6. Schumock GT, Thornton JP (1992) Focusing on preventability of adverse drug reactions. Hosp Pharm 27:538
7. Roughead EE, Gilbert LA, Primrose GJ, Sansom NL (1998) Drug-related hospital admissions: a review of Australian studies published 1988-1996. Med J Aust 168:405-408
8. Goettler M, Schneeweiss S, Hasford J (1997) Adverse drug reaction monitoring - cost and benefit considerations part II: cost and preventability of adverse drug reactions leading to hospital admission. Pharmacoepidemiol Drug Saf 6(Suppl 3): 79-90
9. Lagnaoui R, Moore N, Fach J, Longy-Boursier M, Begaud B (2000) Adverse drug reactions in a department of systemic diseases-oriented internal medicine: prevalence, incidence, direct costs and avoidability. Eur J Clin Pharmacol 55:181-186
10. Olivier P, Boulbès O, Tubery M, Carles P, Montastruc JL, Lapeyre-Mestre M (2001) Evitabilité des effets indésirables dans un service d'admissions médicales. Thérapie 56:275-278
11. Horen B, Montastruc JL, Lapeyre-Mestre M (2002) Adverse drug reactions and off-label drug use in paediatric outpatients. Br J Clin Pharmacol 54:665-670
12. Olivier P, Boulbes O, Tubery M (2002) Assessing the feasibility of using an adverse drug reaction preventability scale in clinical practice. Drug Saf 25:1035-1044
13. Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ et al (2004) Adverse drug reactions as cause of admission to hospital: prospective analysis of 18,820 patients. BMJ 329:15-19
14. Imbs JL, Pletan Y, Spriet A et les membres de la table ronde no2 de Giens XIII (1998) Evaluation de la iatrogénèse médicamenteuse évitable: méthodologie. Therapie 53:365-370
15. Thomas EJ, Brennan TA (2000) Incidence and types of preventable adverse events in elderly patients: population based review of medical records. BMJ 320:741-744
16. Gurwitz JH, Field TS, Avorn J, McCormick D, Jain S, Eckler M et al (2000) Incidence and preventability of adverse drug events in nursing homes. Am J Med 109:87-94
17. Jankel AC, Fitterman KL (1993) Epidemiology of drug-drug interactions as a cause of hospital admissions. Drug Saf 9:51-59
18. Jankel AC, Speedie MS (1990) Detecting drug interactions: a review of the literature. DICP, Ann Pharmacother 24:982-989
19. Albaladejo P, Caillet B, Moine P, Vigué B, Decorps-Declère A, Benhamou D (2001) Prescription hors autorisation de mise sur le marché en réanimation chirurgicale adulte. Presse Med 30:1484-1488
20. Brosgart CL, Mitchell T, Charlebois E, Coleman R, Mehalko S, Young J, et al (1996) Off-label drug use in human immunodeficiency virus disease. J Acquir Immune Defic Syndr 12:56-62
21. Rayburn WF, Turnbull GL (1995) Off-label drug prescribing on a state university obstetric service. J Reprod Med 40:186-188
22. Poole SG, Dooley MG (2004) Off-label prescribing in oncology. Support Care Cancer 12:302-3055
23. Choonara I, Conroy S (2002) Unlicensed and off-label drug use in children - implications for safety. Drug Saf 25:1-5
24. Turner S, Nunn AJ, Fielding K, Choonara I (1999) Adverse drug reactions to unlicensed and off-label drugs on paediatric wards: a prospective study. Acta Paediatr 88:965-968
25. Gill AM, Leach HJ, Hughes J, Barker C, Nunn AJ, Choonara I (1995) Adverse drug reactions in a paediatric intensive care unit. Acta Paediatr 84:438-441
26. Clarkson A, Ingleby E, Choonara I, Bryan P, Arlett P (2001) A novel scheme for the reporting of adverse drugs reactions. Arch Dis Child 84:337-339